|
|
|
|
If you are having trouble viewing this email, please view it in your browser. |
|
|
|
|
 |
|
|
|
|
|
|
Marinova Newsletter |
|
|
December 2015 |
|
|
|
|
|
|
|
Welcome from Paul Garrott, CEO
As the year draws to a close, it is with great pleasure that I can announce that Marinova has been selected as the Australian Nutraceutical Ingredients Company of the Year in the 2015 Frost & Sullivan Awards. This award is in recognition of the company’s achievements across all facets of its business operations – particularly the successful commercialisation of research and development. I would like to take this opportunity to thank all of our personnel and research collaborators for their exceptional contributions in making this award possible.
On a related note, I am also proud to report that 2015 has also been a year of record investment in research and development at Marinova. Our sustained commitment to applied research continues to bear fruit, with eight articles already published in scientific journals, and the initial findings from our cancer trials at the University of Texas nearing publication.
In this issue, we report on the latest published research on Maritech® fucoidans, highlighting their profound bioactivity towards disease-causing bacteria Helicobacter pylori and gastric cancer. The newsletter also features the latest research findings on fucoidan in liver and kidney disease, why we should all include seaweed in our daily diet, and Marinova’s attendance at key international events in 2016.
Until the next edition, I would like to take this opportunity to wish all of our clients, suppliers, research providers and associates a joyful and safe festive season and a very happy New Year!
|
|
|
In this issue
Quick links
|
|
|
|
|
|
|
|
|
|
|
|
|
2015 Nutraceutical Ingredients Company of the Year
|
|
|
Marinova CEO, Mr Paul Garrott, receives the 2015 Nutraceutical Company of the Year Award from Mr Mark Dougan, Managing Director of Frost & Sullivan (Australia & NZ). READ MORE
|
|
|
|
|
Maritech® Fucoidan: treatment hope for peptic ulcers |
|
|
|
|
New in vitro research highlights the profound ability of Maritech® fucoidans to remove Helicobacter pylori from infected cells and alleviate gastric cancer.
Helicobacter pylori (H. pylori) is a bacteria that infects more than half of the human population worldwide. Infection of this bacteria is a primary cause of chronic stomach inflammation, peptic ulcer diseases and gastric cancers, leading to more than one million deaths per year... READ MORE >
|
|
|
|
|
Fucoidan protects against liver disease |
|
Fucoidan ameliorates non-alcoholic fatty liver disease and insulin resistance in rats, according to new research published in Environmental Toxicology and Pharmacology. Non-alcoholic fatty liver disease (NAFLD) is defined as an accumulation of more than 5-10% of fat in the liver in the absence of significant alcohol or drug consumption. NAFLD is strongly associated with obesity and type 2 diabetes and is the most common cause of chronic liver disease worldwide... READ MORE >
|
|
|
|
|
|
|
Fucoidan in the headlines |
|
|
|
Fucoidan protects liver against inflammation
|
|
 |
|
Scientific research has shown fucoidan imparts protective effects towards the heart and kidneys, post-transplant. Until now, limited research has been undertaken to assess whether fucoidan imparts these protective effects on the liver. In new research, fucoidan-fed rats were analysed in comparison to a control group following liver damage. The study found fucoidan provided significant protection to the liver, by suppressing various inflammatory mechanisms. FULL ARTICLE >
|
|
Fucoidan inhibits growth of Leukaemia cells
|
|
 |
|
New data strengthening fucoidan’s anti-cancer activity has shown the extract to have profound bioactivity towards SKM-1 cells – diseased blood cells of Myelodysplastic syndromes (MDS). MDS are a group of myeloid disorders characterised by a high risk of progression to some forms of leukaemia. The study showed fucoidan inhibited proliferation, induced apoptosis and caused arrest of the cell cycle in SKM-1 cells, providing substantial evidence towards the therapeutic potential of fucoidan in MDS treatment. FULL ARTICLE >
|
|
Fucoidan inhibits diabetic kidney disease
|
|
 |
|
Kidney disease is a frequent consequence of long-term diabetes. Fibrosis occurs, making the kidneys ‘scarred’ and no longer functional. Using diabetic rat models, researchers have shown that oral fucoidan inhibits this progression. In the study, it appeared that fucoidan inhibited the fibrotic process, possibly as a result of hindering growth factor pathways. This research points the way forward to fucoidan application as a dietary intervention in chronic diabetes. FULL ARTICLE >
|
|
|
|
|
|
Why you need seaweed in your daily bread |
|
Researchers from the University of Southern Denmark have concluded that adding seaweed to food products, such as pizza and bread, will help reduce the rate of cardiovascular disease (CVD) and related conditions, such as obesity. CVD is the leading cause of premature death globally, according to the World Health Organisation, and is often preventable. The review paper published in Phycologia discusses how food manufacturers facilitate the overconsumption... READ MORE >
|
|
|
|
|
Meet Marinova: Upcoming events in 2016
|
|
|
|
|
|
|
 |
|
Natural Products Expo West
Meet: Mr Kevin Krail (Business Development Manager)
When: 9th - 13th March, 2016
Where: Anaheim Convention Center, Anaheim, CA, USA
Natural Products Expo West website >
|
|
|
|
|
 |
|
Vitafoods Europe
Meet: Mr Kevin Krail (Business Development Manager)
When: 10th - 12th May, 2016
Where: Palexpo, Geneva, Switzerland
Vitafoods Europe website >
|
|
|
|
|
 |
|
22nd International Seaweed Symposium
Meet: Dr Damien Stringer (Operations Manager)
When: 19th - 24th June 2016
Where: Scandic Hotel, Copenhagen, Denmark
ISS website >
|
|
|
|
|
|
Investing into the future of science |
|
Marinova is pleased to welcome Ms Natalie Benbow, PhD student at The University of South Australia (UniSA), to the Company for a short-term laboratory placement. Ms Benbow is currently studying polyelectrolyte multilayers (PEMs) at the Surface Interactions and Soft Matter (SISM) Group, Future Industries Institute (UniSA). PEMs have little recognition within the public field, but are widely used across a range of industries, including bioengineering... READ MORE >
|
|
|
|
|
|
|
|
|
|
Not interested anymore? Unsubscribe. |
|
|
|
|